Vitamin D deficiency is associated with coronary artery calcification in cardiovascularly asymptomatic African Americans with HIV infection
Shenghan Lai,1–4 Elliot K Fishman,2 Gary Gerstenblith,3 Jeffrey Brinker,3 Hong Tai,1 Shaoguang Chen,1 Ji Li,4 Wenjing Tong,1 Barbara Detrick,1 Hong Lai2
1Department of Pathology, 2Department of Radiology, 3Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; 4Department of Epidemiology, John Hopkins University, Johns Hopkins Bloomberg School of Public Heath, Baltimore, MD, USA
Objective: Patients with HIV infection are at increased risk for coronary artery disease (CAD), and growing evidence suggests a possible link between vitamin D deficiency and clinical/subclinical CAD. However, the relationship between vitamin D deficiency and coronary artery calcification (CAC), a sensitive marker for subclinical CAD, in those with HIV infection is not well investigated.
Methods: CAC was quantified using a Siemens Cardiac 64 scanner, and vitamin D levels and the presence of traditional and novel risk factors for CAD were obtained in 846 HIV-infected African American (AA) participants aged 25 years or older in Baltimore, MD, USA without symptoms or clinical evidence of CAD.
Results: The prevalence of vitamin D deficiency (25-hydroxy vitamin D <10 ng/mL) was 18.7%. CAC was present in 238 (28.1%) of the 846 participants. Logistic regression analysis revealed that the following factors were independently associated with CAC: age (adjusted odds ratio [OR]: 1.11; 95% confidence interval [CI]: 1.08–1.14); male sex (adjusted OR: 1.71; 95% CI: 1.18–2.49); family history of CAD (adjusted OR: 1.53; 95% CI: 1.05–2.23); total cholesterol (adjusted OR: 1.006; 95% CI: 1.002–1.010); high-density lipoprotein cholesterol (adjusted OR: 0.989; 95% CI: 0.979–0.999); years of cocaine use (adjusted OR: 1.02; 95% CI: 1.001–1.04); duration of exposure to protease inhibitors (adjusted OR: 1.004; 95% CI: 1.001–1.007); and vitamin D deficiency (adjusted OR: 1.98; 95% CI: 1.31–3.00).
Conclusion: Both vitamin D deficiency and CAC are prevalent in AAs with HIV infection. In order to reduce the risk for CAD in HIV-infected AAs, vitamin D levels should be closely monitored. These data also suggest that clinical trials should be conducted to examine whether vitamin D supplementations reduce the risk of CAD in this AA population.
Keywords: African Americans, HIV infection, antiretroviral therapy, coronary artery calcification, vitamin D deficiency
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Other article by this author:
Vitamin D deficiency is associated with development of subclinical coronary artery disease in HIV-infected African American cocaine users with low Framingham-defined cardiovascular risk
Lai H, Fishman EK, Gerstenblith G, Moore R, Brinker JA, Keruly JC, Chen S, Detrick B, Lai S
Published Date: 15 November 2013
Readers of this article also read:
Gefarnate stimulates mucin-like glycoprotein secretion in conjunctival tissue and ameliorates corneal epithelial damage in animal dry-eye models
Dota A, Takaoka-Shichijo Y, Nakamura M
Published Date: 29 January 2013
Intraperitoneal injection of magnetic Fe3O4-nanoparticle induces hepatic and renal tissue injury via oxidative stress in mice
Ma P, Luo Q, Chen J, Gan Y, Du J, Ding S, Xi Z, Yang X
Published Date: 5 September 2012
Monzon JG, Dancey J
Published Date: 5 March 2012
Armstead AL, Li B
Published Date: 9 December 2011
Fabricio F Costa, Luciano S Foly, Marcelo P Coutinho
Published Date: 18 March 2011
Ali Asghar Darzi, Arsalan Aliramaji, Mir Saeid Ramezani
Published Date: 7 December 2010
Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery
Stephen Smith, Douglas Lorenz, James Peace, et al.
Published Date: 30 August 2010
Management of COPD in general practice in Denmark – participating in an educational program substantially improves adherence to guidelines
Charlotte Suppli Ulrik, Ejvind Frausing Hansen, Michael Skov Jensen, et al
Published Date: 11 March 2010
A Patel, Andrew C Heinrich, Bobby Y Reddy, Pranela Rameshwar
Published Date: 4 February 2009